Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design

Autor: Jaclyn Carberry, Mark C. Petrie, Matthew M.Y. Lee, Katriona Brooksbank, Ross T. Campbell, Richard Good, Pardeep S. Jhund, Peter Kellman, Ninian N. Lang, Kenneth Mangion, Patrick B. Mark, Alex McConnachie, John J.V. McMurray, Barbara Meyer, Vanessa Orchard, Aadil Shaukat, Stuart Watkins, Paul Welsh, Naveed Sattar, Colin Berry, Kieran F. Docherty
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: ESC Heart Failure, Vol 11, Iss 4, Pp 2001-2012 (2024)
Druh dokumentu: article
ISSN: 2055-5822
74029819
DOI: 10.1002/ehf2.14830
Popis: Abstract Aims Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are at risk of progressive adverse cardiac remodelling that can lead to the development of heart failure and death. The early addition of a sodium‐glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in these patients. Methods and results EMpagliflozin to PREvent worSening of left ventricular volumes and Systolic function after Myocardial Infarction (EMPRESS‐MI) is a randomized, double‐blind, placebo‐controlled, multi‐centre trial designed to assess the effect of empagliflozin on cardiac remodelling evaluated using cardiovascular magnetic resonance (CMR) in 100 patients with left ventricular systolic dysfunction following MI. Eligible patients were those ≥12 h and ≤14 days following acute MI, with an LVEF
Databáze: Directory of Open Access Journals
Externí odkaz: